{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:02Z","timestamp":1793676362528,"version":"4.5.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4t des Saarlandes","id":[{"id":"https:\/\/ror.org\/01jdpyv68","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Terbium-161 (\n                      <jats:sup>161<\/jats:sup>\n                      Tb) has emerged as a promising radionuclide for radioligand therapy (RLT) due to its emission of Auger and conversion electrons, which may support therapeutic efficacy through increased local energy deposition. Despite growing research efforts aimed at the clinical potential of\n                      <jats:sup>161<\/jats:sup>\n                      Tb, dosimetric data, particularly for tumor lesions, remain scarce. To address this gap, we assessed tumor and organ dosimetry in mCRPC patients treated with [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study involved\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915 patients with metastasized castration-resistant prostate cancer (mCRPC) participating in a registry (NCT04833517) and receiving [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617. All patients received a median of 2 (range: 1\u20133) cycles with mean administered activity of 6.0\u2009\u00b1\u20091.3 GBq and mean cumulative activity of 12.3\u2009\u00b1\u20094.6 GBq [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617. Hybrid dosimetry of organs at risk, including the salivary glands, the kidneys, the liver, and tumor lesions was performed analyzing whole-body planar and SPECT\/CT images. Absorbed doses were estimated using OLINDA\/EXM for\n                      <jats:sup>161<\/jats:sup>\n                      Tb. Tumor-to-organ ratios (TR) of mean tumor-absorbed doses over relevant organs at risk were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean absorbed dose to kidneys, parotid glands, submandibular glands and liver was 0.70\u2009\u00b1\u20090.41\u00a0Gy\/GBq, 0.40\u2009\u00b1\u20090.20\u00a0Gy\/GBq, 0.36\u2009\u00b1\u20090.14\u00a0Gy\/GBq and 0.13\u2009\u00b1\u20090.08\u00a0Gy\/GBq, respectively. Tumor kinetics in 43 lesions demonstrated stable activity over time (mean half-life of all lesions: 44.07\u00a0h\u2009\u00b1\u200915.88\u00a0h) delivering a mean overall absorbed tumor dose of 5.95\u2009\u00b1\u20093.60\u00a0Gy\/GBq, the resulting TR over kidney and parotid gland were 10.55\u2009\u00b1\u20098.32 and 16.15\u2009\u00b1\u200911.85, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617 delivers high tumor-absorbed doses with tolerable doses to relevant organs at risk, translating into favorable tumor-to-normal-organ ratios. Dosimetry results confirm\n                      <jats:sup>161<\/jats:sup>\n                      Tb as a promising radionuclide for PSMA-targeted radioligand therapy in mCRPC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08171-z","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:31:03Z","timestamp":1788845463000},"page":"8519-8530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-5786","authenticated-orcid":false,"given":"Andrea","family":"Schaefer-Schuler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Petto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Speicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz B.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"8171_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"8171_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract"},{"key":"8171_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76\u201385. https:\/\/doi.org\/10.1038\/ncpuro1296.","journal-title":"Nat Clin Pract Urol"},{"key":"8171_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311. https:\/\/doi.org\/10.1038\/nrc4016.","journal-title":"Nat Rev Cancer"},{"key":"8171_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1055\/s-0043-1774733","volume":"22","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A. Theranostics in developing countries: Addressing challenges and potentials from training to practice. World J Nucl Med. 2023;22:171\u20133. https:\/\/doi.org\/10.1055\/s-0043-1774733.","journal-title":"World J Nucl Med"},{"key":"8171_CR6","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals. Multidisciplinary Digit Publishing Inst. 2022;15:1292. https:\/\/doi.org\/10.3390\/ph15101292.","journal-title":"Multidisciplinary Digit Publishing Inst"},{"key":"8171_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"8171_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"8171_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"8171_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05525-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8171_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-021-00801-w","volume":"16","author":"D Meyrick","year":"2021","unstructured":"Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. Real-world data analysis of efficacy and survival after lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer. Target Oncol. 2021;16:369\u201380. https:\/\/doi.org\/10.1007\/s11523-021-00801-w.","journal-title":"Target Oncol"},{"key":"8171_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s13139-023-00804-7","volume":"57","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Scott AM. 161Tb-PSMA unleashed: a promising new player in the theranostics of prostate cancer. Nucl Med Mol Imaging. 2023;57:168\u201371. https:\/\/doi.org\/10.1007\/s13139-023-00804-7.","journal-title":"Nucl Med Mol Imaging"},{"key":"8171_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/RLU.0000000000004589","volume":"48","author":"F Rosar","year":"2023","unstructured":"Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC. Clin Nucl Med. 2023;48:433\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000004589.","journal-title":"Clin Nucl Med"},{"key":"8171_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","volume":"26","author":"JP Buteau","year":"2025","unstructured":"Buteau JP, Kostos L, Jackson PA, Xie J, Haskali MB, Alipour R, et al. First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta\u2013Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study. Lancet Oncol. 2025;26:1009\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(25)00332-8.","journal-title":"Lancet Oncol"},{"key":"8171_CR15","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.7150\/thno.115831","volume":"15","author":"F Rosar","year":"2025","unstructured":"Rosar F, Burgard C, Petrescu C, Blickle A, Bartholom\u00e4 M, Maus S, et al. Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. Theranostics. 2025;15:9019\u201328. https:\/\/doi.org\/10.7150\/thno.115831.","journal-title":"Theranostics"},{"key":"8171_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.115.170423","volume":"57","author":"E Hindi\u00e9","year":"2016","unstructured":"Hindi\u00e9 E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759\u201364. https:\/\/doi.org\/10.2967\/jnumed.115.170423.","journal-title":"J Nucl Med"},{"key":"8171_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","volume":"7","author":"ME Alcocer-\u00c1vila","year":"2020","unstructured":"Alcocer-\u00c1vila ME, Ferreira A, Quinto MA, Morgat C, Hindi\u00e9 E, Champion C. Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. EJNMMI Phys. 2020;7:33. https:\/\/doi.org\/10.1186\/s40658-020-00301-2.","journal-title":"EJNMMI Phys"},{"key":"8171_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s13139-024-00891-0","volume":"59","author":"AS Abdlkadir","year":"2025","unstructured":"Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, et al. Harnessing terbium radioisotopes for clinical advancements: A systematic review. Nucl Med Mol Imaging. 2025;59:50\u201361. https:\/\/doi.org\/10.1007\/s13139-024-00891-0.","journal-title":"Nucl Med Mol Imaging"},{"key":"8171_CR19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/pharmaceutics13040536","volume":"13","author":"F Borgna","year":"2021","unstructured":"Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, et al. Simultaneous visualization of 161Tb- and 177Lu-labeled somatostatin analogues using dual-isotope SPECT imaging. Pharmaceutics. 2021;13:536. https:\/\/doi.org\/10.3390\/pharmaceutics13040536.","journal-title":"Pharmaceutics"},{"key":"8171_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","volume":"41","author":"C M\u00fcller","year":"2014","unstructured":"M\u00fcller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41:476\u201385. https:\/\/doi.org\/10.1007\/s00259-013-2563-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8171_CR21","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919\u201330. https:\/\/doi.org\/10.1007\/s00259-019-04345-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8171_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","volume":"10","author":"FA Verburg","year":"2023","unstructured":"Verburg FA, de Blois E, Koolen S, Konijnenberg MW. Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection. EJNMMI Phys. 2023;10:69. https:\/\/doi.org\/10.1186\/s40658-023-00589-w.","journal-title":"EJNMMI Phys"},{"key":"8171_CR23","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","volume":"14","author":"A Schaefer-Schuler","year":"2024","unstructured":"Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, et al. [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617. Theranostics. 2024;14:1829\u201340. https:\/\/doi.org\/10.7150\/thno.92273.","journal-title":"Theranostics"},{"key":"8171_CR24","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med"},{"key":"8171_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-026-08037-4","author":"M Misirci","year":"2026","unstructured":"Misirci M, Rosar F, Khreish F, Burgard C, Blickle A, Bartholom\u00e4 M, et al. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort. Eur J Nucl Med Mol Imaging. 2026. https:\/\/doi.org\/10.1007\/s00259-026-08037-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8171_CR26","doi-asserted-by":"publisher","first-page":"112171","DOI":"10.1016\/j.apradiso.2025.112171","volume":"226","author":"F Rosar","year":"2025","unstructured":"Rosar F, Petto S, Ganz S, Burgard C, Maus S, Bartholom\u00e4 M, et al. Assessment of scintigraphic imaging with Terbium-161: A visual and quantitative analysis. Appl Radiat Isot. 2025;226:112171. https:\/\/doi.org\/10.1016\/j.apradiso.2025.112171.","journal-title":"Appl Radiat Isot"},{"key":"8171_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K. MIRD Pamphlet 26: Joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nuclear Med Soc Nuclear Med. 2016;57:151\u201362. https:\/\/doi.org\/10.2967\/jnumed.115.159012.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"8171_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","volume":"53","author":"YK Dewaraja","year":"2012","unstructured":"Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310\u201325. https:\/\/doi.org\/10.2967\/jnumed.111.100123.","journal-title":"J Nucl Med"},{"key":"8171_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","volume":"8","author":"F Rosar","year":"2021","unstructured":"Rosar F, Sch\u00f6n N, Bohnenberger H, Bartholom\u00e4 M, Stemler T, Maus S, et al. Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys. 2021;8:40. https:\/\/doi.org\/10.1186\/s40658-021-00385-4.","journal-title":"EJNMMI Phys"},{"key":"8171_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1109\/TMI.2008.2012036","volume":"28","author":"M Hatt","year":"2009","unstructured":"Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging. 2009;28:881\u201393. https:\/\/doi.org\/10.1109\/TMI.2008.2012036.","journal-title":"IEEE Trans Med Imaging"},{"key":"8171_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP. 2002;32:1\u2013277.","journal-title":"Ann ICRP"},{"key":"8171_CR32","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"8171_CR33","first-page":"242506","volume":"65","author":"J Buteau","year":"2024","unstructured":"Buteau J, McIntosh L, Jackson P, Emmerson B, Kostos L, Alipour R, et al. Radiation absorbed dose in patients with metastatic castration-resistant prostate cancer treated with [161Tb]Tb-PSMA-I&T. J Nuclear Med Soc Nuclear Med. 2024;65:242506\u2013242506.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"8171_CR34","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","volume":"65","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B, et al. Clinical Trial protocol for VIOLET: A single-center, phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. J Nucl Med. 2024;65:1231\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267650.","journal-title":"J Nucl Med"},{"key":"8171_CR35","doi-asserted-by":"publisher","unstructured":"EANM\u201923 Abstract Book Congress Sep 9\u201313. 2023. Eur J Nucl Med Mol Imaging. 2023;50:1\u2013898. https:\/\/doi.org\/10.1007\/s00259-023-06333-x","DOI":"10.1007\/s00259-023-06333-x"},{"key":"8171_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","volume":"38","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38:91. https:\/\/doi.org\/10.1097\/MNM.0000000000000606.","journal-title":"Nucl Med Commun"},{"key":"8171_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med"},{"key":"8171_CR38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","volume":"65","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: A comparative systematic review and metaanalysis. J Nucl Med. 2024;65:1264\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.267452.","journal-title":"J Nucl Med"},{"key":"8171_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2967\/jnumed.121.262671","volume":"63","author":"B Feuerecker","year":"2022","unstructured":"Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, et al. Pretherapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63:833\u20139. https:\/\/doi.org\/10.2967\/jnumed.121.262671.","journal-title":"J Nucl Med"},{"key":"8171_CR40","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1097\/RLU.0000000000006384","volume":"51","author":"F Rosar","year":"2026","unstructured":"Rosar F, Burgard C, Hoang SPT, Blickle A, Bartholom\u00e4 M, Maus S, et al. Outcome and safety of radioligand therapy with [161Tb]Tb-PSMA-617 after re-progression in mCRPC patients previously treated with [177Lu]Lu-PSMA-617. Clin Nucl Med. 2026;51:e356\u201361. https:\/\/doi.org\/10.1097\/RLU.0000000000006384.","journal-title":"Clin Nucl Med"},{"key":"8171_CR41","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.2967\/jnumed.122.264953","volume":"64","author":"M Hohberg","year":"2023","unstructured":"Hohberg M, Reifegerst M, Drzezga A, Wild M, Schmidt M. Prediction of response to 177Lu-PSMA therapy based on tumor-to-kidney ratio on pretherapeutic PSMA PET\/CT and posttherapeutic tumor-dose evaluation in mCRPC. J Nucl Med. 2023;64:1758\u201364. https:\/\/doi.org\/10.2967\/jnumed.122.264953.","journal-title":"J Nucl Med"},{"key":"8171_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.zemedi.2026.03.011","author":"S Resch","year":"2026","unstructured":"Resch S, Delker A. State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies. Z Med Phys. 2026. https:\/\/doi.org\/10.1016\/j.zemedi.2026.03.011.","journal-title":"Z Med Phys"},{"key":"8171_CR43","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00259-024-06827-2","volume":"51","author":"SD Busslinger","year":"2024","unstructured":"Busslinger SD, Mapanao AK, Kegler K, Bernhardt P, Fl\u00fchmann F, Fricke J, et al. Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting. Eur J Nucl Med Mol Imaging. 2024;51:4049\u201361. https:\/\/doi.org\/10.1007\/s00259-024-06827-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8171_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2022","unstructured":"Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, et al. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113\u201326. https:\/\/doi.org\/10.1007\/s00259-021-05564-0.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08171-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08171-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08171-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:41Z","timestamp":1793672981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08171-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":44,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8171"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08171-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the local institutional review board (\u00c4rztekammer des Saarlandes\/Saarbr\u00fccken; ethics committee permission number 140\/17).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for the publication of any resulting data in anonymized form.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}